IL3 receptor-dependent therapeutic targeting of BCR-ABL-driven lymphoid leukemias.
Williams
Richard T
RT
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D016185:Receptors, Interleukin-3 / Q000378:metabolism*
D000970:Antineoplastic Agents; D016185:Receptors, Interleukin-3; D016044:Fusion Proteins, bcr-abl